Skip to main content
Premium Trial:

Request an Annual Quote

Prenetics' ACT Genomics Profiling Test for Solid Tumors Receives FDA Clearance

NEW YORK – Genomic and diagnostic testing company Prenetics Global said Tuesday that the US Food and Drug Administration has cleared ACTOnco, a comprehensive genomic profiling test for solid tumors.

ACTOnco was developed by ACT Genomics, a Taipei, Taiwan-based precision oncology company of which Hong Kong-based Prenetics acquired a majority stake in December.

The ACTOnco diagnostic test analyzes 440 cancer-associated genes to support clinicians prescribing targeted oncology therapies, such as immunotherapies. The test can be used for solid tumors including breast, colon, endometrial, and lung cancers.

The decision makes Prenetics the first company based in Asia to receive FDA clearance for a comprehensive genomic profiling test, according to the firm.

"While precision medicine provides an advantage in disease diagnosis and treatment planning and has become a routine clinical practice in the west, it is not the case in Asia," said Hua Chien Chen, CEO of ACT Genomics, in a statement. Unlike most tests developed by US companies, which mainly use clinical samples from Western countries, half of the samples to develop and validate the ACTOnco assay came from Western and half from Asian countries, he said. 

Prenetics plans to continue to invest in R&D efforts related to early cancer detection, said Danny Yeung, chairman of ACT Genomics and CEO of Prenetics, in a statement.

The company's investment in ACT Genomics served as an entry point into the global precision oncology market, the firm said. Prenetics did not disclose financial terms of its agreement to acquire a majority of ACT Genomics in December, but said it would issue 19.9 million shares of its ordinary stock to ACT Genomics and pay $20 million in cash.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.